Sanofi steps up with its da­ta on a new MS drug, shin­ing a spot­light on PhI­II hopes af­ter fend­ing off a short at­tack

Sanofi CEO Paul Hud­son was drawn ear­ly on in his new job to a mul­ti­ple scle­ro­sis drug in the pipeline, talk­ing it up ahead of the mid-stage da­ta and lat­er re­serv­ing a promi­nent place in the late-stage pipeline on the top-line read­out. Sanofi has start­ed to map out an am­bi­tious Phase III ef­fort aimed at tak­ing it over the com­mer­cial line — even as they face de­lays in­flict­ed by Covid-19.

On Thurs­day morn­ing, re­searchers spelled out the da­ta for the Phase IIb that give them con­fi­dence that SAR442168 has the po­ten­tial to play a dis­rup­tive role in the MS mar­ket — where some tough com­peti­tors are roil­ing the field even as physi­cians and pa­tients con­tin­ue to press for more choic­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER